In vitro cytotoxic and molecular effects of metoprolol, alone or combined with cisplatin, on colon cancer cells
DOI:
https://doi.org/10.60988/p.v37i2S.164Keywords:
metoprolol; cisplatin; colon cancer cells; cell viability; cytotoxicityAbstract
Colorectal cancer ranks among the most prevalent malignancies worldwide, with surgical interventions frequently associated with substantial postoperative mortality and complications. Contemporary therapies often target molecular pathways such as the epidermal growth factor receptor and vascular endothelial growth factor. Recently, antihypertensive agents have been investigated for their potential anticancer properties, though results remain inconclusive. This study has assessed the cytotoxic effects of metoprolol, both as a monotherapy and in combination with cisplatin, on the SW480 colon cancer cell line using the MTT assay. Cisplatin achieved the highest cytotoxic activity at a concentration of 62.5 µg/mL, while metoprolol alone exhibited maximal cell-killing effects at 1,000 µg/mL. Notably, the combination of metoprolol (1,000 µg/mL) with cisplatin (15.6 µg/mL) demonstrated the most pronounced cytotoxic effect, thereby indicating potential synergistic activity. The findings suggest the potential of repurposing metoprolol as an adjunctive agent in combination chemotherapy, in order to enhance therapeutic outcomes in colorectal cancer treatment.
References
1. Tiefenthal M., Asklid D., Hjern F., Matthiessen P., Gustafsson U.O. Laparoscopic and open right-sided colonic resection in daily routine practice. A prospective multicentre study within an Enhanced Recovery After Surgery (ERAS) protocol. Colorectal Dis. 18(2), 187–194, 2016. DOI: 10.1111/codi.13082
2. Anderson A.D., McNaught C.E., MacFie J., Tring I., Barker P., Mitchell C.J. Randomized clinical trial of multimodal optimization and standard perioperative surgical care. Br. J. Surg. 90(12), 1497–1504, 2003. DOI: 10.1002/bjs.4371
3. Giampieri R., Scartozzi M., Del Prete M., Maccaroni E., Bittoni A., Faloppi L., et al. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit. Rev. Oncol. Hematol. 88(2), 272–283, 2013. DOI: 10.1016/j.critrevonc.2013.05.008
4. Padwal R.S., Bienek A., McAlister F.A., Campbell N.R.; Outcomes Research Task Force of the Canadian Hypertension Education Program. Epidemiology of hypertension in Canada: an update. Can. J. Cardiol. 32(5), 687–694, 2016. DOI: 10.1016/j.cjca.2015.07.734
5. Qi J., Bhatti P., Spinelli J.J., Murphy R.A. Antihypertensive medications and risk of colorectal cancer in British Columbia. Front. Pharmacol. 14, 1301423, 2023. DOI: 10.3389/fphar.2023.1301423
6. Cheung K.S., Chan E.W., Seto W.K., Wong I.C.K., Leung W.K. ACE (angiotensin-converting enzyme) inhibitors / angiotensin receptor blockers are associated with lower colorectal cancer risk: a territory-wide study with propensity score analysis. Hypertension 76(3), 968–975, 2020. DOI: 10.1161/HYPERTENSIONAHA.120.15317
7. Cho I.J., Shin J.H., Jung M.H., Kang C.Y., Hwang J., Kwon C.H., et al. Antihypertensive drugs and the risk of cancer: a nationwide cohort study. J. Clin. Med. 10(4), 771, 2021. DOI: 10.3390/jcm10040771
8. van Meerloo J., Kaspers G.J., Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol. Biol. 731, 237–245, 2011. DOI: 10.1007/978-1-61779-080-5_20
9. Hajatbeigi B., Hajighasemi F. Cytotoxicity of metoprolol on leukemic cells in vitro. Iran. J. Blood Cancer 10(4), 124–129, 2018.
10. Caldwell G.W., Masucci J.A., Chacon E. High throughput liquid chromatography-mass spectrometry assessment of the metabolic activity of commercially available hepatocytes from 96-well plates. Comb. Chem. High Throughput Screen. 2(1), 39–51, 1999.
